

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 20, 2021

MOTION ACQUISITION CORP.  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-39618  
(Commission File Number)

85-2515483  
(IRS Employer  
Identification No.)

c/o Graubard Miller  
405 Lexington Avenue, 11th Floor  
New York, NY  
(Address of Principal Executive Offices)

10174  
(Zip Code)

Registrant's telephone number, including area code: (212) 818-8877

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of Class A Common Stock and one-third of one redeemable warrant	MOTNU	The Nasdaq Stock Market LLC
Class A Common Stock, par value \$0.0001 per share	MOTN	The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of Class A Common Stock at an exercise price of \$11.50 per share	MOTNW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 7.01 Regulation FD Disclosure

As previously announced, Motion Acquisition Corp., a Delaware corporation (“**Parent**”), has entered into a Merger Agreement (the “**Merger Agreement**”) by and among Parent, Motion Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“**Merger Sub**”), and Ambulnz, Inc. (dba DocGo), a Delaware corporation (the “**Company**”).

Attached as Exhibit 99.1 to this Current Report on Form 8-K is an updated form of investor presentation used by the Company on May 20, 2021 during the Needham 16th Annual Virtual Technology & Media Conference, and which may be used by Parent and the Company in presentations regarding the proposed business combination.

The information set forth under this Item 7.01, including the exhibit attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“**Exchange Act**”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

#### Additional Information and Where to Find It

Parent and the Company intend to hold presentations for persons who might be interested in purchasing Parent’s securities, in connection with the proposed transactions with the Company. This Current Report on Form 8-K, including the exhibit hereto, may be distributed to participants at such presentations.

Parent intends to file a registration statement on Form S-4 with the SEC, which will include a document that serves as a prospectus and proxy statement of Parent, referred to as a proxy statement/prospectus, and certain related documents, to be used at the meeting of Parent’s stockholders to approve the proposed business combination and related matters. **Investors and security holders of Parent are urged to read the registration statement, the proxy statement/prospectus, and any amendments thereto, and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about Parent, the Company, and the proposed transaction.** The definitive proxy statement will be mailed to Parent’s stockholders as of a record date to be established for voting on the proposed business combination. Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Parent, once such documents are filed, through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov).

The documents filed by Parent with the SEC also may be obtained free of charge at Parent’s website at <https://motionacquisition.com> or upon written request to Motion’s counsel, Graubard Miller, 405 Lexington Avenue, New York, NY 10174.

The information contained on, or that may be accessed through, the websites referenced in this Current Report on Form 8-K is not incorporated by reference into, and is not a part of, this Current Report on Form 8-K.

### **Participants in Solicitation**

Parent, the Company, and certain of their respective directors and executive officers, under SEC rules, may be deemed to be participants in the eventual solicitation of proxies from Parent's stockholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be contained in the proxy statement/prospectus when available. You may obtain free copies of these documents as described in the preceding paragraphs.

### **No Offer or Solicitation**

This Current Report on Form 8-K and the exhibit hereto shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This Current Report on Form 8-K also shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

### **Forward-Looking Statements**

Certain statements included in this Current Report on Form 8-K and the exhibit hereto are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity.

These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Parent and the Company. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions. Further, these forward-looking statements are subject to a number of risks and uncertainties, including: the conditions to the completion of the Merger, including the required approval by Parent's stockholders, may not be satisfied on the terms expected or on the anticipated schedule; the parties' ability to meet expectations regarding the timing and completion of the Merger; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; the approval by Parent's stockholders of an amendment to Parent's organizational documents to extend the date by which Parent must complete its initial business combination in order to have adequate time to close the proposed transaction; the outcome of any legal proceedings that may be instituted against Parent related to the merger or the Merger Agreement; the amount of the costs, fees, expenses and other charges related to the merger; the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination; failure to realize the anticipated benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to the Company; the Company's ability to successfully expand its service offerings; competition; the uncertain effects of the COVID-19 pandemic; and those factors discussed in the registration statement, proxy statement/prospectus, and other documents filed, or to be filed, by Parent with SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither Parent nor the Company presently know or that Parent and the Company currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

In addition, forward-looking statements reflect Parent's and the Company's expectations, plans or forecasts of future events and views as of the date of this Current Report on Form 8-K. Parent and the Company anticipate that subsequent events and developments will cause Parent's and the Company's assessments to change. However, while Parent and the Company may elect to update these forward-looking statements at some point in the future, Parent and the Company specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Parent's and the Company's assessments as of any date subsequent to the date of this Current Report on Form 8-K. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Any financial projections in this Current Report on Form 8-K or the exhibit hereto are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond Parent's and the Company's control. While all projections are necessarily speculative, Parent and the Company believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the projections. The inclusion of projections in this press release should not be regarded as an indication that Parent and the Company, or their respective representatives and advisors, considered or consider the projections to be a reliable prediction of future events.

This Current Report on Form 8-K, including its exhibit, is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in Parent and is not intended to form the basis of an investment decision in Parent. All subsequent written and oral forward-looking statements concerning Parent and the Company, the proposed business combination or other matters and attributable to Parent, the Company, or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

<u>Exhibit</u>	<u>Description</u>
99.1	<a href="#">Investor Presentation</a>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 20, 2021

**MOTION ACQUISITION CORP.**

By: /s/ Rick Vitelle  
Rick Vitelle  
Chief Financial Officer



WHERE TELEHEALTH STOPS, WE GO

INVESTOR  
PRESENTATION  
*MAY 2021*

# Disclaimer



This presentation contemplates a business combination pursuant to a merger agreement, by and among Ambulnz Inc. (dba "DocGo"), Motion Acquisition Corp. ("Motion"), and a wholly owned subsidiary of Motion, dated as of March 9, 2021. This presentation discusses the proposed transaction and does not purport to be all-inclusive or to give you any legal, tax or financial advice. This presentation does not constitute or involve, and should not be taken as constituting or involving, the giving of any investment advice, the making of any representation, warranty or covenant whatsoever, or as a recommendation with respect to the voting, purchase or sale of any security or as to any other matter by DocGo, Motion or any other person.

Although the information contained herein is believed to be accurate, DocGo and Motion, as well as each of their respective directors, officers, shareholders, members, partners and representatives, expressly disclaim liability for, and makes no expressed or implied representation or warranty with respect to, any information contained in or omitted from this presentation, or any other information or communication (whether written or oral) transmitted to any prospective investor. Only those representations and warranties made in a definitive agreement with any person shall have any legal effect.

This presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination between DocGo and Motion or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of Motion, any company forming a part of DocGo or any of their respective affiliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Investors should make their own independent investigation of DocGo and Motion before investing in any securities.

PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

#### Use of Projections and Financial Information

This presentation contains financial forecasts relating to the anticipated future financial performance of the proposed combination of DocGo and Motion and are subject to risks and uncertainties that could cause actual results to differ materially from those statements and should be read with caution. They are subjective in many respects and thus susceptible to interpretations and periodic revisions based on actual experience and recent developments. While presented with numerical specificity, the projections were not prepared in the ordinary course and are based upon a variety of estimates and hypothetical assumptions made by management of DocGo and Motion with respect to, among other things, general economic, market, interest rate and financial conditions, the availability and cost of capital for future investment, and competition within DocGo's markets. The projections were not prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for prospective financial information or generally accepted accounting principles in the United States of America ("GAAP").

None of the assumptions underlying the projections may be realized, and they are inherently subject to significant business, economic and competitive uncertainties and risks, all of which are difficult to predict and many of which are beyond the control of DocGo and Motion. Accordingly, there can be no assurance that the assumptions made in preparing the projections will prove accurate, and actual results may materially differ. Furthermore, while all projections are necessarily speculative, DocGo and Motion believe that prospective financial information covering periods beyond 12 months from its date of preparation carries increasingly higher levels of uncertainty and should be read in that context.

For these reasons, as well as the bases and assumptions on which the projections were compiled, the inclusion of the information set forth below should not be regarded as an indication that the projections will be an accurate prediction of future events, and they should not be relied on as such. Neither DocGo nor Motion or any of their respective affiliates, advisors or other representatives has made, or makes, any representation to any stockholder or prospective investor regarding the information contained in the projections and, except as required by applicable securities laws, neither DocGo nor Motion intends to update or otherwise revise the projections to reflect circumstances existing after the date when made or to reflect the occurrences of future events even in the event that any or all of the assumptions are shown to be in error.

#### Non-GAAP Financial Information

This presentation also includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with GAAP, such as Earnings Before Interest, Tax, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA. As a result, such information may not conform to SEC Regulation S-X and may be adjusted and presented differently in Motion's filing with the SEC. Any non-GAAP financial measures used in this presentation are in addition to, and should not be considered superior to, or a substitute for, financial statements prepared in accordance with GAAP. Non-GAAP financial measures are subject to significant inherent limitations. The non-GAAP measures presented herein may not be comparable to similar non-GAAP measures presented by other companies. This information may be presented differently in future filings by the company with the SEC.

# Disclaimer (cont'd)



## Market and Industry Data

Market data and industry data used throughout this presentation is based on information derived from third party sources, the knowledge of the management teams of DocGo and Motion regarding their respective industries and businesses and respective management teams' good faith estimates. While management of DocGo and Motion believe that the third party sources from which market and industry data has been derived are reputable, DocGo and Motion have not independently verified such market and industry data, and you are cautioned not to give undue weight to such market and industry data.

## Additional Information and Where to Find It

This presentation relates to a proposed transaction between DocGo and Motion. Motion intends to file a registration statement on Form S-4 with the SEC, which will include a document that serves as a prospectus and proxy statement of Motion, referred to as a proxy statement/prospectus, and certain related documents, to be used at the meeting of Motion stockholders to approve the proposed business combination and related matters. Investors and security holders of Motion are urged to read the registration statement, the proxy statement/prospectus, and any amendments thereto, and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about DocGo, Motion, and the proposed transaction. The definitive proxy statement will be mailed to Motion stockholders as of a record date to be established for voting on the proposed business combination. Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Motion, once such documents are filed, through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov).

The documents filed by Motion with the SEC also may be obtained free of charge at Motion's website at <https://motionacquisition.com> or upon written request to Motion's counsel, Graubard Miller, 405 Lexington Avenue, New York, NY 10174.

## Solicitation Participants

DocGo and Motion and their respective officers and directors, under SEC rules, may be deemed to be participants in the eventual solicitation of proxies of Motion's stockholders in connection with the proposed transaction. Prospective investors may obtain more detailed information regarding the names and interests in the proposed transaction of such individuals in Motion's filings with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be contained in the proxy statement/prospectus when available. You may obtain free copies of these documents as described in the preceding paragraph.

## Forward Looking Statements

Certain statements included in this presentation are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity.

These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of DocGo's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of DocGo and Motion. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions. Further, these forward-looking statements are subject to a number of risks and uncertainties, including: the conditions to the completion of the merger, including the required approval by DocGo's and Motion's stockholders, may not be satisfied on the terms expected or on the anticipated schedule; the parties' ability to meet expectations regarding the timing and completion of the merger; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the approval by Motion's stockholders of an amendment to Motion's organizational documents to extend the date by which Motion must complete its initial business combination in order to have adequate time to close the proposed transaction; the outcome of any legal proceedings that may be instituted against Motion related to the merger or the merger agreement; and the amount of the costs, fees, expenses and other charges related to the merger; the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination; failure to realize the anticipated benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to DocGo, DocGo's ability to successfully expand its service offerings; competition; the uncertain effects of the COVID-19 pandemic; and those factors discussed in the registration statement, proxy statement/prospectus, and other documents filed, or to be filed, by Motion with SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither DocGo nor Motion presently know or that DocGo and Motion currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DocGo's and Motion's expectations, plans or forecasts of future events and views as of the date of this presentation. DocGo and Motion anticipate that subsequent events and developments will cause DocGo's and Motion's assessments to change. However, while DocGo and Motion may elect to update these forward-looking statements at some point in the future, DocGo and Motion specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing DocGo's and Motion's assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.



# Disclaimer (cont'd)



## Forward Looking Statements (cont'd)

Any financial projections in this presentation are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond DocGo's and Motion's control. While all projections are necessarily speculative, DocGo and Motion believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the projections. The inclusion of projections in this presentation should not be regarded as an indication that DocGo and Motion, or their respective representatives and advisors, considered or consider the projections to be a reliable prediction of future events.

This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in Motion and is not intended to form the basis of an investment decision in Motion. All subsequent written and oral forward-looking statements concerning DocGo and Motion, the proposed business combination or other matters and attributable to Motion, DocGo, or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

## Other Disclaimers

No representation or warranty, express or implied, can be made or is made by DocGo or Motion as to the accuracy or completeness of any such information. Except where otherwise indicated, this presentation speaks as of the date hereof and is necessarily based upon the information as of the date hereof, all of which are subject to change. DocGo and Motion have no obligation to update, bring-down, review or reaffirm this presentation. Under no circumstances should the delivery of this presentation imply that any information or analyses included in this presentation would be the same if made as of any other date. Nothing contained in this presentation is, or shall be relied upon as, a promise or representation as to the past, present or future.

This presentation provides summary information only and is being delivered solely for informational purposes. The recipient of this presentation acknowledges that:

- DocGo and Motion do not provide legal, tax or accounting advice of any kind.
- It is not relying on DocGo or Motion for legal, tax or accounting advice, and that the recipient should receive separate and qualified legal, tax and accounting advice in connection with any transaction or course of conduct.
- Nothing contained herein shall be deemed to be a recommendation from DocGo or Motion to any party to enter into any transaction or to take any course of action.
- This presentation is not intended to provide a basis for evaluating any transaction or other matter.
- Neither DocGo nor Motion shall have any liability, whether direct or indirect, in contract or tort or otherwise, to any person in connection with this presentation.


INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAS ANY REGULATORY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR SOLICITATION OF ANY SECURITIES.

## Our Brand and Company Culture

*Where basic telehealth providers stop, we go.  
Where public health emergencies need a response,  
we go. Where homebound populations benefit from  
onsite treatment, we go. Where long waits in busy  
emergency rooms do more harm than good, we go.  
And when all reason says it can't be done, leave  
well enough alone and quit while you're ahead, we  
do what our Company has always done.*

**DocGo. We go.**

## Our Model



**Fulfilling the Promise of Telehealth by Enabling the  
"Last-Mile" Delivery of Healthcare**

# DocGo at a Glance



## Key Highlights



Leveraging a **proprietary technology platform** and **care logistics expertise** to provide high quality, efficient **“last-mile” healthcare delivery services**

<sup>(a)</sup> As of May 15, 2021.

# Where Traditional Care Stops, DocGo Keeps Going



## Traditional Care vs. TeleHealth Plus

### Traditional Care

- ✗ Patients are restricted by outdated logistics and expensive transportation solutions
- ✗ Limited options to get treated at home or on-site
- ✗ Current telehealth offerings do not provide immediate in-person care or follow-up as needed

### DocGo TeleHealth Plus Solution

- ✓ Mobility solutions that are enabled by highly coordinated and efficient logistics capabilities
- ✓ TeleHealth Plus offering goes far beyond traditional telehealth capabilities, delivering true "last-mile" services
- ✓ Unique solution set plugs seamlessly into existing care ecosystem

# Telemedicine is Just Talk – TeleHealth Plus is Hands On



DocGo. We're There.

Leveraging Advanced, Mobile Technologies to Deliver Robust Services

Vaccinations



Bloodwork



IV Hydration



Wound Care





Oral Medicine Administration



Mobile Imaging



EKG



## For Patients...

- ✓ At home treatment is convenient, comfortable and results in an improved patient experience
- ✓ Accessibility to health professionals promotes better patient compliance with discharge treatment plans
- ✓ More focused care reduces unnecessary hospital readmissions

## For Providers...

- ✓ DocGo employed providers, consisting of paramedics and EMTs, can provide care at a lower cost than LPNs/LVNs or physicians
- ✓ Reduces overall healthcare costs by preventing unnecessary flow of patients into healthcare facilities

Note: EMT = Emergency Medical Technician, LPN = Licensed Practical Nurse, LVN = Licensed Vocational Nurse.

# Differentiated Approach Creates Efficiency and Cost Savings




## Enabling Dramatic TeleHealth Plus Cost Advantage

Leverages paramedics, EMTs, CNAs and LPNs to provide care, lowering employment costs for hospitals and patients vs. traditional methods



Cost of common procedures, such as vaccination and bloodwork, are executed at a fraction of the industry average



Source: Management estimates. Note: Figures above are presented for illustrative purposes only. CNA = Certified Nursing Assistant.

# Transportation Serves as Foundation for Operational Leverage



Drives margin improvement and competitive advantage


## Transportation Model Advantages

- Innovative JV model
- Highly predictable transport volume
- Integrated platform changes the way facilities manage patient transports, improves operational efficiencies and aligns incentives
- Employed providers and not contractors
- Lays profitable foundation to upsell idle time



## Competitive Differentiators

- Provides opportunity to build highly defensible model by selecting mix of transportation / TeleHealth Plus per geography to optimize gross margin
- Differentiates against pure plays by offering two different products to build in geography credibility and cross sell with major providers
- Superior employee attraction and retention model to source the best talent
- Logical framework to execute M&A strategy combined with the ability to grow margins and cash flow ratios



Pediatrics / Neonatal Intensive Care Unit  
Critical Care Transport



Basic Life Support  
Advanced Life Support



Wheelchair Accessible Vehicle  
Ambulette



Car

Fully integrated solution provider facilitating high-quality, efficient patient transportation across all sites of care

# Purpose-Built Technology Platform



## Core Functionality and Benefits


- ✓ Streamlined ordering process to reduce burden on staff
- ✓ Integration of electronic health records to enhance functionality & billing/collections **Epic** Allscripts
- ✓ Easy ordering with no manual information transfer
- ✓ Real-time visibility into transport status and ordering
- ✓ Fully integrated with bed management systems
- ✓ Predictive resource allocation to estimate patient discharge

For **Patients and Families**

For **Care Providers**

For **Facilities**

For **Peace of Mind**



**Two apps. One location-based dispatch system. Connected.**





# JV Partners Help Drive Predictable Growth



## FRESENIUS

- Premier global dialysis provider with 2,600+ dialysis centers and 205k+ patients
- Transportation JV partner

## Jefferson

- Largest Philadelphia region hospital system with 14 hospitals, 5 urgent care, 22 rehab and 19 outpatient centers
- Transportation and TeleHealth Plus JV partner

## uchealth

- #1 health care system in Colorado, also serving Southern Wyoming and Western Nebraska<sup>(a)</sup>
- Transportation JV partner

## RXR

- Leading real estate owner and operator in New York City
- TeleHealth Plus JV partner, providing on-site testing, monitoring, reporting and verification



**\$500M+ per year combined revenue opportunity<sup>(b)</sup>**



**Evergreen contract structure with multi-year cancellation notice periods**



**Highly recurring and predictable revenue**



**National footprint across JVs**

**DocGo is in advanced talks with several large hospital systems and national healthcare companies to expand its JV partnerships**

(a) According to U.S. News and World Report.  
(b) Based on management estimates.

# Illustrative Customers & Partners



Tailored Go-to-Market for each Customer Segment

## Government

## Enterprise / Corporates


## Health Systems

The image displays a grid of logos for three customer segments: Government, Enterprise / Corporates, and Health Systems. The Government segment includes logos for the State of California, City of Philadelphia, PHL Philadelphia International Airport, Miami-Dade County, and New York State Department of Health. The Enterprise / Corporates segment includes logos for Barclays Center, Borgata, Carnival, City, Equinox, GoodRx, HBO, Javits Center, MDI, MLB, NFL, RXR, Uber, BLADE, and W Hotels. The Health Systems segment includes logos for Fresenius Medical Care, HCA Healthcare, Jefferson, Long Island Select Healthcare, Inc., Mount Sinai, Northwell Health, and uchealth.

# Significant Market Opportunity

**\$95 billion market opportunity** leaving long runway for rapid growth

## U.S. Total Addressable Market



Source: McKinsey "Telehealth: A quarter-trillion-dollar post-COVID-19 reality" report published 5/1/20 and management estimates.

© 2021 All Rights Reserved - DocGo



- Payers, providers and patients are motivated to push services to the home
- Approx. \$250B or 20% of all Medicare, Medicaid & Commercial outpatient, office and home health spend **could be virtual**
- However, approx. **\$80B of this spend requires some form of physical follow up** that lacks a solution today
- The medical transportation industry remains very fragmented and is **expected to continue to grow steadily**, driven by an increasingly aging population and rising prevalence of chronic diseases

# Experienced Management Team



Presenting Today



**Stan Vashovsky**  
Co-Founder, Chief Executive Officer



**Andre Oberholzer**  
Chief Financial Officer

- Founded DocGo in 2015 with the vision to revolutionize medical transportation and healthcare delivery
- Previously an executive for services innovations at Philips Healthcare
- 25+ years of healthcare experience including in the field as a paramedic
- Joined in 2015 with experience developing companies throughout their business lifecycle including M&A / integration
- Previously in financial roles at Philips and Altegrity and CFO of WageWorks
- 20+ years of finance and operations experience



**Anthony Capone**  
President



**Vrenly Munoz**  
Chief Revenue Officer



**Ari Moradmand**  
Chief Technology Officer



**Norm Rosenberg**  
CFO of Ambulnz Holdings, LLC



**Rosemarie Milano**  
VP, Human Resources

# Key Takeaways



Significant market and growth opportunity with limited current market penetration

Early stages of accelerating recurring revenue growth

Unique value proposition to healthcare systems and patients

Defensible competitive advantages in technology / network

Highly attractive financial profile with significant operating leverage

Mission-driven company with experienced founder-led management



# Financial Overview

---

# Highly Attractive Financial Characteristics



Significant revenue growth opportunity with limited existing penetration


Visibility to recurring revenue growth with existing JV partners

Scalable business model with robust operating leverage

Capital efficient approach enables rapid expansion in existing and into new markets





# Recurring, Predictable Revenue Model



# Strong Growth Trajectory and Margin Profile



(\$ in millions)



Note: PCAOB audits for 2019 and 2020 are in process.



(a) Free Cash Flow is defined as Adjusted EBITDA less Capital Expenditures.

© 2021 All Rights Reserved - DocGo

- Substantial growth through the expansion of existing JV contracts and markets
- New market expansion within existing joint venture relationships contributes to revenue acceleration
- TeleHealth Plus acceleration drives operating leverage and margin expansion
- Capital efficient model to support continued growth
- Strong platform for acquisitions

# Q1 2021 Financial Update

(\$ in millions)



## Preliminary First Quarter 2021 Financial Highlights and Full-Year Outlook

- Excluding Covid-related testing, Q1 revenue more than doubled
- TeleHealth Plus revenue increased to nearly \$30 million, compared to \$0.5 million in Q1 2020
- DocGo is raising its outlook for full-year 2021 revenue guidance from \$155 million to \$160 million+

## First Quarter 2021 Business Highlights

- Expanded TeleHealth Plus offerings, with home visit programs for Long Island Select Healthcare in New York and Martin Luther King Hospital in Los Angeles
- Completed rollout of 40 mobile testing units for NYC Health + Hospitals and NYC Test & Trace Corps, and became a leading facilitator of COVID vaccinations in NY State



# Transaction Overview

---

# Pro Forma Capitalization & Ownership



## Estimated Transaction Sources & Uses

(\$ in millions)

### Sources

SPAC Cash in Trust	\$115
PIPE Investor Cash	\$125
<b>Total Sources</b>	<b>\$240</b>

### Uses

Cash to Balance Sheet	\$205
Transaction Expenses	\$35
<b>Total Uses</b>	<b>\$240</b>

(a) Assumes no redemptions of public shares and excluding warrants.  
 (b) Does not include an aggregate 5.0M seller earnout shares subject to vesting upon attainment of stock price targets ranging from \$12.50 to \$21.00 over periods ranging from one to five years. Excludes Motion warrants.


## Post-Money Valuation at Close

(\$ in millions)


### Pro forma Transaction

DocGo Illustrative Share Price	\$10.00
Pro forma Shares Outstanding <sup>(a)(b)</sup>	110.5
<b>Total Equity Value</b>	<b>\$1,105</b>
(+) Proforma Net Debt at Close	(205)
<b>Pro forma Enterprise Value</b>	<b>\$900</b>

## Illustrative Post-Transaction Ownership<sup>(b)</sup>




# Comparable Company Benchmarking



(a) Pro forma for the acquisition of 2ND.MD; 2019 figures represents standalone ACCD; excludes earnout consideration associated with the 2ND.MD acquisition.  
 (b) Excludes the pending acquisition of Fluhcare.  
 (c) Pro forma for Livongo Health acquisition.  
 Source: Company information, FactSet. Market data as of 18-May-21.

# Comparable Company Benchmarking (cont'd)



Note: Excludes multiples > 100.0x.  
 (a) Excludes the pending acquisition of Plushcare.  
 Source: Company information, FactSet. Market data as of 18-May-21.



# Appendices

---



# Non-GAAP Adjusted EBITDA Reconciliation



<i>(\$ in thousands)</i>	<u>CY2020E</u>
<b>Net Loss Attributable to DocGo</b>	<b>(\$15,049)</b>
(+) Loss of JV	(213)
<b>Net Loss (GAAP)</b>	<b>(\$15,262)</b>
(+) Net Interest Expense / (Income)	608
(+) Income Tax	167
(+) Depreciation & Amortization	5,689
<b>EBITDA</b>	<b>(\$8,798)</b>
(+) Non-Cash Stock Compensation	687
(+) Non-Recurring Expense	1,000
<b>Adjusted EBITDA</b>	<b>(\$7,111)</b>

*Note: PCAOB audits for 2020 are in process.*